Article

4 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    8 4 0 0


Joint Bone Spine
Volume 71, n° 6
pages 503-510 (novembre 2004)
Doi : 10.1016/j.jbspin.2004.03.004
Received : 2 June 2003 ;  accepted : 19 Mars 2004
Signal transduction pathways: new targets for treating rheumatoid arthritis
 

Jacques Morel a, , Francis Berenbaum b
a Immunorheumatology Department and Inserm U454, CHU Lapeyronie Hospital, 371, avenue du Doyen Gaston Giraud, 34295 Montpellier cedex 5, France 
b Rheumatology Department and UMR 7079 CNRS/Paris 6, Saint Antoine Hospital, Paris, France 

*Corresponding author.
Abstract

Biotherapies and other new treatments introduced over the last few years have considerably enriched the therapeutic armamentarium for rheumatoid arthritis. Nevertheless, primary refractoriness or secondary escape phenomenon may occur, indicating a need for identifying new treatment targets. Promising candidates can be found among compounds involved in signal transduction pathways, most notably protein kinases (mitogen-activated protein kinase, MAPK and phosphatidylinositol-3 protein kinase, PI3) and transcription factors (nuclear factor kappa B, NF-κB; activating protein 1, AP-1; CCAAT/enhancer-binding protein, C/EBP and signal transducer and activator of transcription, STAT). Inhibition of signal transduction pathways may be achievable via three main strategies: pharmacological inhibitors, anti-sense or more specific inhibitors such as oligionucleotides or interfering mRNA, and induced overexpression of naturally occurring inhibitors. Clinical trials are under way to evaluate pharmacological inhibitors such as p38 MAPK. Although the preliminary results are promising, proof of safety has not yet been obtained. Signal transduction pathways are involved in normal processes, whose inhibition might produce untoward effects.

The full text of this article is available in PDF format.

Keywords : Signal transduction pathways, Pharmacological inhibitors, Anti-sense oligonucleotides, Rheumatoid arthritis, Inflammation, Gene therapy, Mitogen-activated protein kinase, Suppressors of cytokine signaling




© 2004  Éditions scientifiques et médicales Elsevier SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline